Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 12/2007

01-12-2007 | Clinical Trials

Participation in Surgical Oncology Clinical Trials: Gender-, Race/Ethnicity-, and Age-based Disparities

Authors: John H. Stewart, IV, MD, Alain G. Bertoni, MD, MPH, Jennifer L. Staten, BS, Edward A. Levine, MD, Cary P. Gross, MD

Published in: Annals of Surgical Oncology | Issue 12/2007

Login to get access

Abstract

Objective

To characterize the representation of racial/ethnic minorities, women, and older persons among participants in surgical trials sponsored by the National Cancer Institute (NCI).

Methods

The NCI Clinical Trial Cooperative Group surgical oncology trials database was queried for breast, colorectal, lung, and prostate cancers treated during the period 2000–2002 (n=13,991). Data from the SEER program and the Census were used to estimate age-, gender-, and race/ethnicity-specific incidence of the same cancers among U.S. adults during the same period. Enrollment fraction (EF), defined as the number of trial enrollees divided by the estimated U.S. cancer cases in each demographic group, was the primary outcome measure. Logistic regression was used to compare the enrollment of racial/ethnic, gender and age subgroups in this analysis.

Results

Relative to white patients (EF=0.72%), lower EFs were noted in African-American (0.48%, odds ratio[OR] vs whites 0.67, P<0.001), Hispanic (0.54%, OR 0.76, P<0.001), and Asian/Pacific islander (0.59%, OR 0.82, P=0.001) patients. Overall, women were more likely to enroll in surgical trials (1.12%) than men (0.22%, OR 5.06, P<0.001). Patients 65–74 years of age (EF 0.45%) were less likely to be enrolled than those 20–44 years of age (EF=2.28%, OR 0.20, P=0.001).

Conclusions

The enrollment in surgical oncology trials is very low across all demographics. However, racial/ethnic minorities and older persons are less likely to be enrolled in cooperative group surgical oncology trials than are whites and younger patients. The high EF for women is due to the high availability of trials for women with breast cancer. Strategies to increase accrual to surgical trials and ameliorate disparities related to race/ethnicity, gender, and age are needed.
Literature
1.
Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341:2061–2067PubMedCrossRef
2.
Tejeda HA, Green SB, Trimble EL, et al. Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials. J Natl Cancer Inst 1996; 88:812–816PubMedCrossRef
3.
Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 2004; 291:2720–2726PubMedCrossRef
4.
Tournoux C, Katsahian S, Chevret S, et al. Factors influencing inclusion of patients with malignancies in clinical trials. Cancer 2006; 106:258–270PubMedCrossRef
5.
Newman LA, Hurd T, Leitch M, et al. A report on accrual rates for elderly and minority-ethnicity cancer patients to clinical trials of the American College of Surgeons Oncology Group. J Am Coll Surg 2004; 199:644–651PubMedCrossRef
6.
Gross CP, Murthy V, Li Y, et al. Cancer trial enrollment after state-mandated reimbursement. J Natl Cancer Inst 2004; 96:1063–1069PubMedCrossRef
7.
Swanson GM, Ward AJ. Recruiting minorities into clinical trials: toward a participant-friendly system. J Natl Cancer Inst 1995; 87:1747–1759PubMedCrossRef
8.
Gbadegesin S, Wendler D. Protecting communities in health research from exploitation. Bioethics 2006; 20:248–253PubMedCrossRef
9.
Adams-Campbell LL, Ahaghotu C, Gaskins M, et al. Enrollment of African Americans onto clinical treatment trials: study design barriers. J Clin Oncol 2004; 22:730–734PubMedCrossRef
10.
11.
Shavers VL, Lynch CF, Burmeister LF. Factors that influence African-Americans’ willingness to participate in medical research studies. Cancer 2001; 91:233–236PubMedCrossRef
12.
Mouton CP, Harris S, Rovi S, et al. Barriers to black women’s participation in cancer clinical trials. J Natl Med Assoc 1997; 89:721–727PubMed
13.
Shavers-Hornaday VL, Lynch CF, Burmeister LF, et al. Why are African Americans under-represented in medical research studies? Impediments to participation. Ethn Health 1997; 2:31–45PubMedCrossRef
14.
Lathan CS, Neville BA, Earle CC. The effect of race on invasive staging and surgery in non-small-cell lung cancer. J Clin Oncol 2006; 24:413–418PubMedCrossRef
15.
Lara PN Jr., Higdon R, Lim N, et al. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol 2001; 19:1728–1733PubMed
16.
Gross CP, Herrin J, Wong N, et al. Enrolling older persons in cancer trials: the effect of sociodemographic, protocol, and recruitment center characteristics. J Clin Oncol 2005; 23:4755–4763PubMedCrossRef
17.
Townsley C, Pond GR, Peloza B, et al. Analysis of treatment practices for elderly cancer patients in Ontario, Canada. J Clin Oncol 2005; 23:3802–3810PubMedCrossRef
18.
Cohen JJ, Gabriel BA, Terrell C. The case for diversity in the health care workforce. Health Aff (Millwood) 2002; 21:90–102CrossRef
Metadata
Title
Participation in Surgical Oncology Clinical Trials: Gender-, Race/Ethnicity-, and Age-based Disparities
Authors
John H. Stewart, IV, MD
Alain G. Bertoni, MD, MPH
Jennifer L. Staten, BS
Edward A. Levine, MD
Cary P. Gross, MD
Publication date
01-12-2007
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 12/2007
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-007-9500-y

Other articles of this Issue 12/2007

Annals of Surgical Oncology 12/2007 Go to the issue

Gastrointestinal Oncology

Simultaneous Resections of Colorectal Cancer and Synchronous Liver Metastases: A Multi-institutional Analysis

Editorials

Intrahepatic Lymphatic Invasion Independently Predicts Poor Survival and recurrences after Hepatectomy in Patients with Colorectal Carcinoma Liver Metastases

Thoracic Oncology

Combined Prognostic Value of Both RelA and IκB-α Expression in Human Non–Small Cell Lung Cancer

Gastrointestinal Oncology

Prognostic Significance of Osteopontin Expression in Human Gastric Carcinoma

Gastrointestinal Oncology

Epithelial-Mesenchymal Transition (EMT) and Activated Extracellular Signal-regulated Kinase (p-Erk) in Surgically Resected Pancreatic Cancer

Gastrointestinal Oncology

Pretreatment Gene Expression Profiles Can Be Used to Predict Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer